v3.25.1
Condensed Consolidated Statements of Cash Flows
9 Months Ended
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Cash flow from operating activities:    
Net loss $ (1,094,760) $ (965,370)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 930,341 525,267
Stock options expense 146,751 104,502
Restricted common stock expense 1,400,199 1,603,820
Modification cost of accelerated vesting of restricted common stock   20,949
Adjustment to contingent earnout liability 2,812,796 (268,287)
Changes in operating assets and liabilities:    
Accounts receivable (754,258) (739,883)
Prepaid expenses and other current assets 17,826 (156,026)
Prepaid royalties 311,938 197,888
Accounts payable and accrued expenses (338,502) 498,584
Deferred revenue 1,331,920 768,347
Net cash provided by (used in) operating activities 4,764,251 1,589,791
Cash flow from investing activities:    
Purchase of property and equipment (11,571) (57,761)
Net cash used in investing activities (11,571) (10,081,507)
Cash flow from financing activities:    
Common stock repurchase (908,393) (522,024)
Payment of contingent acquisition consideration (91,174) (314,960)
Net cash used in financing activities (999,567) (836,984)
Effect of exchange rate changes (1,137) 4,791
Net increase (decrease) in cash and cash equivalents 3,751,976 (9,323,909)
Cash and cash equivalents, beginning of period 6,100,031 13,545,333
Cash and cash equivalents, end of period 9,852,007 4,221,424
Supplemental disclosures of cash flow information:    
Cash paid for income taxes 74,816 82,049
Non-cash investing and financing activities:    
Contingent consideration accrual on asset acquisition $ 29,394 36,130
Resolute    
Cash flow from investing activities:    
Payment for acquisition, net of cash acquired   (2,718,253)
Scite    
Cash flow from investing activities:    
Payment for acquisition, net of cash acquired   $ (7,305,493)